NCT04202809招募中2 期
Prospective Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus the PD-L1 Antibody Durvalumab Followed by Surgery or Definitive Chemoradiation Boost and Consolidation Durvalumab in Resectable Stage III NSCLC.
University Hospital, Essen7 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2020年1月13日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 90
- 试验地点
- 7
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
To compare a complex induction multimodality protocol (ESPATUE) + concurrent immunotherapy with PD-L1 antibody Durvalumab given every three weeks to the same induction multimodality protocol without Durvalumab immunotherapy induction followed by definitive local treatment (surgery for those considered resectable or chemoradiation boost for those not considered to be R0-resectable) followed by consolidation Durvalumab treatment in both arms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Body weight >30 kg
- •Age ≥ 18 years and < 75 years
- •Male or female patients. Female (as well as male) patients have to take care of effective measures of anticonception
- •Histologically proven non-small cell lung cancer
- •Selected patients with non-small cell lung cancer stages IIIA and IIIB:
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •Resectable disease at the time of inclusion
- •Fulfillment of adequate criteria for functional and medical resectability as described in the European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS) guidelines [Brunelli et al 2009] and acceptable general clinical condition for multimodality treatment (interdisciplinary committee)
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization (e.g, European Union [EU] Data Privacy Directive in the EU) obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
- •Must have a life expectancy of > 12 weeks
- •Adequate normal organ and marrow function
- •Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
- •Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- •Stable cardiac function (no Myocardial infarction (MI) within 6 months, no heart failure according to New York Heart Association (NYHA) III-IV).
排除标准
- •resectable IIB or selected IIIA (T3N0; T3N1)
- •unresectable disease pre-treatment
- •mixed histology with areas of small cell carcinoma (neuroendocrine markers)
- •clinically symptomatic vena cava superior syndrome
- •diffuse mediastinal involvement
- •patients with T3N3 and T4N3 tumors (IIIC according to International Association for the Study of Lung Cancer (IASLC)/Union Internationale Contre le Cancer (UICC) 8)
- •invasion of the thoracic aorta (T4 - aorta)
- •invasion of the heart (except left atrium - T4 - heart)
- •invasion of the esophagus (T4 - esophagus)
- •invasion of spine (T4 - spine)
- •(full blown) Pancoast-syndrome in tumors of the superior sulcus (T3-4 Nx)
- •malignant (positive) pericardial effusion (M1a - pericardial effusion)
- •malignant (positive) pleural effusion (M1a - pleural effusion)
- •involvement of the contralateral hilar nodes (if any data available)
- •endobronchial tumor extension to the contralateral main stem bronchus
- •ipsi- or contralateral supraclavicular nodes (N3 - supraclavicular nodes)
- •lung or heart function not allowing at the time of inclusion the intended surgical procedure
- •previous administration of chemotherapy and/or radiotherapy
- •previous immunotherapy
- •insufficient patients compliance (e.g. symptomatic psychiatric disorder)
- •loss of weight > 10 % in the last six months
- •missing written informed consent or definitive refusal for participation
- •Participation in another clinical study with an investigational product during the last 12 months
- •Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
- •Must not have required the use of additional immunosuppression other than corticosteroids for the management of an Adverse Event (AE), not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day
- •History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan
- •Any concurrent chemotherapy, Intraperitoneal (IP), biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
- •Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
- •History of allogenic organ transplantation.
- •History of a stem cell transplantation
- •Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.]).
- •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
- •History of another primary malignancy
- •History of active primary immunodeficiency
- •Active infection including tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive Hepatitis B Virus (HBV) surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV ½ antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody (anti-HBc) and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •Current or prior use of immunosuppressive medication within 14 days before the first dose of Durvalumab.
- •Current or prior use of immunostimulatory agents within 14 days before the first dose of Durvalumab.
- •Receipt of live attenuated vaccine within 90 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 90 days after the last dose of IP.
- •Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of Durvalumab monotherapy.
- •Known allergy or hypersensitivity to Durvalumab or any excipient
研究组 & 干预措施
Chemo- and Radiochemotherapy + Durvalumab
Experimental
干预措施: Durvalumab (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: 2 years
Two-year progression-free survival rate
次要结局
- Functional response(Week 15)
- Overall survival(after 1, 2, 3, 4 and 5 years)
- RECIST response (induction)(Week 9)
- EORTC QLQ-C30(Through study completion, an average of every 6 weeks for up to 11 months)
- RECIST criteria(Through study completion, an average of every 2 months for up to 11 months)
- 2-y-overall survival rate(2 years)
- EORTC QLQ-LC13(Through study completion, an average of every 6 weeks for up to 11 months)
- FACT-L(Through study completion, an average of every 6 weeks for up to 11 months)
研究者
研究点 (7)
Loading locations...
相似试验
尚未招募
2 期
Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal CarcinomaNasopharyngeal CarcinomaNCT04447326First Affiliated Hospital of Guangxi Medical University106
已完成
2 期
Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaEfficacyToxicityNCT06281886Sun Yat-sen University170
撤回
2 期
Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00210171Institut Bergonié3
招募中
1 期
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/LymphomaNK-Cell LymphomaNK-Cell LeukemiaPeripheral T Cell LymphomaNCT03719105New York Medical College40
进行中（未招募）
2 期
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL AdenocarcinomaGastroEsophageal CancerAdenocarcinomaGastric CancerNCT04069273Harry H Yoon58